Canadian Investment Regulatory Organization Trade Resumption – PEX

Trading resumes in: Company: Pacific Ridge Exploration Ltd. TSX-Venture Symbol: PEX All Issues: Yes Resumption (ET): 11:15 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization […]

Ongoing GSK plc (GSK) Investigation: Protect Your Rights – Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / August 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of GSK plc ("GSK plc") (NYSE:GSK) concerning possible violations of federal securities laws. GSK issued a press release on July 17, 2025, announcing "that the US Food and Drug Administration (FDA) Oncologic Drugs

Securities Class Action Lawsuit Filed Against Hims & Hers Health, Inc. (HIMS) – Levi & Korsinsky Represents Shareholders

NEW YORK, NY / ACCESS Newswire / August 5, 2025 / If you suffered a loss on your Hims & Hers Health, Inc. (NYSE:HIMS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/hims-hers-health-inc-lawsuit-submission-form?prid=159804&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq. via email at

VOLLEYBALL LEAGUES ANNOUNCE HISTORIC PLAN: THE NEW MLV

In a landmark move for the sport, Pro Volleyball Federation (PVF) and Major League Volleyball have announced plans for a single, united league poised to elevate professional women's volleyball in the United States. The unified league will be branded as MLV. https://mma.prnewswire.com/media/2744442/Major_League_Volleyball.jpg This is an exciting moment for professional women's volleyball. The unification and modernization

SOC LAWSUIT ALERT: Levi & Korsinsky Notifies Sable Offshore Corp. Investors – Lead Plaintiff Deadline September 26, 2025

NEW YORK, NY / ACCESS Newswire / August 5, 2025 / If you suffered a loss on your Sable Offshore Corp. (NYSE:SOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sable-offshore-corp-lawsuit-submission-form?prid=159805&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstCapricor Therapeutics, Inc. (“Capricor” or “the Company”) (NASDAQ: CAPR) forviolations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg Investors who purchased the

Capricor Therapeutics, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – CAPR

The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. (“Capricor” or “the Company”) (NASDAQ: CAPR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CAPR during the

Cell Culture Market to Reach USD 71.1 Billion by 2032, Says SkyQuest Technology Consulting

The cell culture market is anticipated to expand at a rapid pace owing to growing innovations in biotechnologies, and biopharmaceuticals on the back of rising demand for monoclonal antibodies and vaccines. SkyQuest Technology Consulting published a report, titled, “Cell Culture Market- Global Opportunity Analysis and Industry Forecast, 2025-2032”, valued at USD 28.76 Billion in 2024.

Liquid Biopsy Market worth US$7.05 billion by 2030 with 11.8% CAGR | MarketsandMarkets™

The global Liquid Biopsy Market, valued at US$3.65 billion in 2024stood at US$4.03 billion in 2025 and is projected to advance at a resilient CAGR of 11.8% from 2025 to 2030, culminating in a forecasted valuation of US$7.05 billion by the end of the period. The increasing global cancer incidence and the growing emphasis on

ASPN: The Trusted DTC Pharmacy Partner — Proven, Live, and Ready for Rapid Implementation

Following last week's update from President Trump reinforcing the May 12, 2025 Executive Order Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients, pharmaceutical manufacturers are now expected to implement direct-to-consumer (DTC) solutions within 60 days. https://mma.prnewswire.com/media/2744453/ASPN_Pharmacies_logo_FullColor.jpg ASPN is already delivering. As a long-standing leader in digital pharmacy services, ASPN has been live withmultiple manufacturer partnersformonths,

Scroll to Top